The world’s top ten pharmaceutical companies in 2019 are released, with Pfizer, Roche, and Johnson & Johnson ranking among the top three

Recently, ProClinical, a world-renowned talent recruitment company in the field of life sciences, ranked the top ten pharmaceutical companies in the world in 2019 based on the revenue of global multinational pharmaceutical companies in 2018:

1. Pfizer< /p>

Revenue in 2018: US$53.7 billion (pharmaceutical business, the same below)

Year-on-year growth: 2.3%

Pfizer is the world’s largest multinational pharmaceutical company , a research-based company with a diverse product portfolio spanning therapeutic areas including immunology, oncology, neuroscience and rare diseases. Despite modest revenue growth, 2018 was still a very successful year for Pfizer.

A number of Pfizer’s new drugs have been approved by the FDA, especially in oncology. In addition, many of its best-selling products have years of patent protection. Pfizer's key products, including Ibrance, Eliquis and Xeljanz, all saw significant growth.

2. Roche

Revenue in 2018: US$45.6 billion

Year-on-year growth: 2.7%

Swiss pharmaceutical company Roche The second largest pharmaceutical company in the world in 2019, Roche has 94,442 employees worldwide. The company develops innovative medicines and devices in a number of key indications, such as oncology, immunology, infectious diseases and neuroscience. The pharmaceutical segment has an annual growth rate of 2.7%, and revenue from the top three products accounted for 40% of Roche's total revenue in 2018 ($57.2 billion).

Roche’s best-selling drugs Herceptin, Avastin and Rituxan are also the world’s top anti-cancer drugs. Roche CEO Severan Schwan reported that new drugs accounted for 90% of the company's growth in 2018, especially the launch of the new multiple sclerosis drug Ocrevus, which has been called the most successful new drug in Roche's history.

3. Johnson & Johnson

Revenue in 2018: US$40.7 billion

Year-on-year growth: 12.1%

Johnson & Johnson was established Founded more than 130 years ago, major brands have become household names thanks to popular consumer products such as Aveeno, Neutrogena and Listerine. It’s worth noting that J&J’s 12.1% growth was partly due to the 2017 acquisition of biopharmaceutical company Actelion, whose products in the pulmonary hypertension portfolio contributed to J&J’s 3.4% growth in 2018. Other growth drivers include top-selling drugs Stelara, Darzalex and Zytiga.

4. Sanofi

Revenue in 2018: US$39.3 billion

Year-on-year growth: 7.1%

French pharmaceutical Sanofi's pharmaceutical revenue grew 7.1% in 2018, accounting for the majority of the company's total revenue. More than 25% of revenue comes from Sanofi's three best-selling drugs, Lantu, an insulin injection to treat diabetes, Lovenox, an anticoagulant to prevent blood clots, and a drug to treat multiple sclerosis. One daily pill of Aubagio.

5. Merck & Co.

Revenue in 2018: US$37.7 billion

Year-on-year growth: 12.2%

U.S. Pharmaceuticals Company Merck develops new drugs, vaccines and biologics in the fields of cardiovascular, oncology, endocrinology and infectious diseases. The company's revenue has grown 12.2% since 2017, driven by the continued success of Merck's best-selling drugs: cancer immunotherapy Keytruda, HPV vaccine Gardasil and diabetes drug Januvia.

6. Novartis

Revenue in 2018: US$34.9 billion

Year-on-year growth: 5.5%

Novartis Switzerland in 2018 Revenues rose 5.8% compared with 2017 figures, even as the company's best-selling drugs face generic competition from top-selling oncology drug imatinib (Gleevec) and antihypertensive drugs hydrochlorothiazide (Diovan) and Amlodipine (Exforge).

In response to these losses, Novartis spent 18% of its 2017 total revenue on research and development in 2018. Currently, Novartis' best-selling drugs are Gilenya for the treatment of multiple sclerosis and Lucentis for patients with degenerative eye diseases.

7. AbbVie

Revenue in 2018: US$32.8 billion

Year-on-year growth: 16.2%

Based on research Dominant US biopharmaceutical company AbbVie maintained its position on the list, growing 16.2% compared to 2017 pharmaceutical revenue statistics.

AbbVie recently announced that its most anticipated drug, upadacitinib, will be used to treat moderate to severe atopic dermatitis and has been granted Breakthrough Therapy Designation by the FDA. This is just one of many promising drugs in AbbVie's diverse portfolio.

8. Amgen

Revenue in 2018: US$23.7 billion

Year-on-year growth: 3.5%

Amgen is An American biopharmaceutical company headquartered in California, focused on research and development in cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Amgen's inclusion on the list is due to the success of various products, including Repatha (up 72% year over year), BLINCYTO (up 31% year over year) and Prolia (up 16% year over year).

In early 2019, Amgen was named one of the pharmaceutical industry's most admired companies by Fortune magazine and ranked fifth on Fast Company's 2019 Most Innovative Companies.

9. GlaxoSmithKline (GSK)

Revenue in 2018: US$23.3 billion

Year-on-year growth: 2%

< p> GlaxoSmithKline (GSK) is a British pharmaceutical company with strong innovative medicines. The company focuses on a broad range of therapeutic areas but is particularly successful in HIV/AIDS, respiratory and vaccines.

Compared with 2017 data, GlaxoSmithKline’s revenue growth rate was 2%, with its best-selling HIV drugs Trivicay and Triumeq, Ellipta treating asthma and chronic obstructive pulmonary disease, and another asthma drug mepolizumab Antibiotic (Nucala) drove sales growth.

Last year GlaxoSmithKline won approval for Shingrix, a product used to treat the herpes zoster virus, with sales of 784 million pounds.

10. Bristol-Myers Squibb

Revenue in 2018: US$22.6 billion

Year-on-year growth: 8.7%

Baidu Bristol-Myers Squibb is an American pharmaceutical company headquartered in New York City. BMS focuses on four key therapeutic areas: oncology, cardiovascular, immunoscience and fibrosis. The company's strong growth in 2018 was partly due to the continued success of lead drugs Oppo (cancer) and Eliquis (blood thinner).

BMS plans to acquire Celgene (an innovative oncology biotechnology) in early 2019, which may further BMS's success.

(Sun Huan/Compiled)

Reference materials: ①ProClinical website: Who are the top 10 pharmaceutical companies in the world? (2019)